Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Ezetimibe
KRKA, d.d., Novo mesto
C10AX; C10AX09
Ezetimibe
10 milligram(s)
Tablet
Product subject to prescription which may be renewed (B)
Other lipid modifying agents; ezetimibe
Marketed
2016-12-02
PACKAGE LEAFLET: INFORMATION FOR THE USER EZETIMIBE KRKA 10 MG TABLETS ezetimibe READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ezetimibe Krka is and what it is used for 2. What you need to know before you take Ezetimibe Krka 3. How to take Ezetimibe Krka 4. Possible side effects 5. How to store Ezetimibe Krka 6. Contents of the pack and other information 1. WHAT EZETIMIBE KRKA IS AND WHAT IT IS USED FOR Ezetimibe Krka is a medicine to lower increased levels of cholesterol. Ezetimibe Krka lowers levels of total cholesterol, “bad” cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. In addition, Ezetimibe Krka raises levels of “good” cholesterol (HDL cholesterol). Ezetimibe, the active ingredient of Ezetimibe Krka, works by reducing the cholesterol absorbed in your digestive tract. Ezetimibe Krka adds to the cholesterol-lowering effect of statins, a group of medicines that reduce the cholesterol your body makes by itself. Cholesterol is one of several fatty substances found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol. LDL cholesterol is often called “bad” cholesterol because it can build up in the walls of your arteries forming plaque. Eventually this plaque build-up can lead to a narrowing of the arteries. This narrowing can slow or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can result in a heart attack or stroke. HDL cholesterol is often called “good” cho Read the complete document
Health Products Regulatory Authority 13 March 2024 CRN00F6CH Page 1 of 15 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ezetimibe Krka 10 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg ezetimibe. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. Tablets are presented as white to off white, capsule shaped tablets with bevelled edges. Tablet dimensions: 8 x 4 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _Primary hypercholesterolaemia_ Ezetimibe Krka, co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia who are not appropriately controlled with a statin alone. Ezetimibe Krka monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia in whom a statin is considered inappropriate or is not tolerated. _Prevention of Cardiovascular Events_ Ezetimibe Krka is indicated to reduce the risk of cardiovascular events (see section 5.1) in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin. _Homozygous Familial Hypercholesterolaemia (HoFH)_ Ezetimibe Krka co-administered with a statin, is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis). Homozygous sitosterolaemia (phytosterolaemia) Ezetimibe Krka is indicated as adjunctive therapy to diet for use in patients with homozygous familial sitosterolaemia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The patient should be on an appropriate lipid lowering diet and should continue on this diet during treatment with Ezetimibe Krka. The recommended dose is one Ezetimibe Krka 10 mg tablet daily. Ezetimibe Krka can be administered at any time of the day, Read the complete document